Stromal tumours of the gastrointestinal tract: a clinicopathological and ploidy analysis of 33 cases

Lerma, Enrique; Oliva, Esther; Tugues, D; Prat, Jaime

doi:10.1007/bf00197388

Cited by 47 publications

(32 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This tumor occurs in both sexes equally (19,26,27) or slightly higher in men as observed in this study (8,23,32) . The primary site of tumors noted arise in the small bowel (40%) or in the stomach (32%) in contrast to others which this tumor commonly arise mostly in the stomach (60%-70%) and in the small intestine in a smaller frequency (26%-35%) (29) .…”

Section: Discussionsupporting

confidence: 70%

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Neves¹,

Oshima²,

Neto³

et al. 2009

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor. Cellular proliferation and apoptosis is gaining importance for predicting prognosis in several cancers. Objective -To investigate the Ki67 and p53 immunostaining in GISTs. Methods -Specimens from 40 patients with GIST were assessed for immunohistochemical expression of Ki67 and p53. The tumors were divided according the risk of recurrence in two groups: I with high or intermediate risk and; II with low or very low risk. Results -Among the 40 patients, 21 were men, the mean age was 56 years, 16 occurred in the small intestine and 13 in the stomach, 5 in the retroperitonium, 4 in the colon or rectum and 2 in the mesenterium. Thirty two tumors were from group I and 8 from group II. Half of the patients developed recurrence, being 90% of the group I (P = 0.114). The tumor Ki67 labelling index ranged from 0.02 to 0.35 (mean level 0.12). This index was marginally higher in the group I patients with recurrence (P = 0.09) compared to the patients of the same group without recurrence. p53 staining was expressed in 65% of the GISTs. A higher frequency of p53 and Ki67 had been found in the group I tumors when compared to the other group (P = 0.022; OR = 8.00 -IC 95%: 1.32-48.65). Conclusion -The most common site was the small intestine and 80% had a malignant potential justifying the high recurrence observed. No significant correlation was found between p53 and overall outcome of the patients. In group I patients, the evaluation Ki67LI may be a marker of prognosis. The positivity of both markers is higher among the patients with worst prognosis than in the others. HEADINGS -Gastrointestinal stromal tumors. Ki-67 antigen. Tumor suppressor protein p53.

show abstract

Section: Discussionsupporting

confidence: 70%

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Neves¹,

Oshima²,

Neto³

et al. 2009

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Ulceration, necrosis and hemorrhage all correlate with risk, although such features are not usually predictive of clinical behavior. However, foci of unequivocal tumor necrosis are generally associated with malignancy (2,12,18,19,22,(30)(31)(32). The status of microscopic margin of resection does not affect survival (13).…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal stromal tumors: A multicenter study of 1160 Turkish cases

DOGUSOY¹,

Group²

2012

Turk J Gastroenterol

View full text Add to dashboard Cite

Amaç: Bu çok merkezli çal›flmada Türkiye'den toplanan gastrointestinal stromal tümör vakalar›nda histopatolojik ve immunohistokimyasal özellikleri belirlemek amaçlanm›flt›r. Yöntem ve Gereç: Oluflturulan ulusal bir veritaban›na 28 merkezden gastrointestinal stromal tümör vakalar› kaydedildi. Gastrointestinal stromal tümör tan›s› hematoksilin-eosin bulgular›na ve CD117, CD34, desmin, SM Actin, ve Ki67'yi içeren antikor paneli sonuçlar›na dayand›r›ld›. Veritaban› yafl, cinsiyet, tümör yeri, di¤er intestine, omentum-peritoneum, large intestine, and esophagus (32.0%, 12.6%, 9.3%, 1.1%, respectively). The risk groups were distributed as: 6.1% very low, 21.7% low, 19.3% intermediate, and 53% high-risk

show abstract

“…Several factors independently predict the prognosis of GISTs following resection. The most important and easily applicable histologic criteria for prediction are tumor size (maximum diameter in cm), and mitotic rate 11,[18][19][20] . A rate of ≤5 mitoses per 50 HPF is commonly used as a limit for a tumor of expected benign behavior, and according to a large study, this can discriminate between benign and malignant gastric tumors, but not between benign and malignant small intestinal tumors 11 .…”

Section: Discussionmentioning

confidence: 99%

Clinical Presentation and Treatment of Gastrointestinal Stromal Tumors

Cipolla

Fulfaro

Sandonato

et al. 2006

Tumori

View full text Add to dashboard Cite

Results:The patients with localized disease treated only by surgery did not relapse. In the patients with locally advanced or metastatic disease treated by imatinib, we observed 3 partial responses, and one case was not assessable because he had no measurable disease. In 2 of 3 responders, it was possible to perform a new radical surgery. Conclusions: Our series is too small to draw any conclusion. According to our review of the literature, surgery remains the standard treatment for non-metastatic GISTs. Imatinib mesylate represents a major breakthrough in the treatment of advanced GISTs and is the first effective systemic therapy for the disease.

show abstract

Stromal tumours of the gastrointestinal tract: a clinicopathological and ploidy analysis of 33 cases

Cited by 47 publications

References 12 publications

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Gastrointestinal stromal tumors: A multicenter study of 1160 Turkish cases

Clinical Presentation and Treatment of Gastrointestinal Stromal Tumors

Contact Info

Product

Resources

About